BR112016025297B1 - Adenovírus que compreende uma porção de ligação a albumina - Google Patents
Adenovírus que compreende uma porção de ligação a albumina Download PDFInfo
- Publication number
- BR112016025297B1 BR112016025297B1 BR112016025297-7A BR112016025297A BR112016025297B1 BR 112016025297 B1 BR112016025297 B1 BR 112016025297B1 BR 112016025297 A BR112016025297 A BR 112016025297A BR 112016025297 B1 BR112016025297 B1 BR 112016025297B1
- Authority
- BR
- Brazil
- Prior art keywords
- adenovirus
- albumin
- protein
- genome
- abd
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/075—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14382162.7A EP2940128A1 (en) | 2014-04-30 | 2014-04-30 | Adenovirus comprising an albumin-binding moiety |
EP14382162.7 | 2014-04-30 | ||
PCT/EP2015/059593 WO2015166082A1 (en) | 2014-04-30 | 2015-04-30 | Adenovirus comprising an albumin-binding moiety |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016025297A2 BR112016025297A2 (pt) | 2017-10-17 |
BR112016025297B1 true BR112016025297B1 (pt) | 2022-08-30 |
Family
ID=50774820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016025297-7A BR112016025297B1 (pt) | 2014-04-30 | 2015-04-30 | Adenovírus que compreende uma porção de ligação a albumina |
Country Status (12)
Country | Link |
---|---|
US (3) | US10604549B2 (he) |
EP (2) | EP2940128A1 (he) |
JP (1) | JP6639412B2 (he) |
KR (1) | KR102628234B1 (he) |
CN (1) | CN106471125B (he) |
AU (1) | AU2015254535B2 (he) |
BR (1) | BR112016025297B1 (he) |
CA (1) | CA2946650C (he) |
IL (1) | IL248590B (he) |
MX (1) | MX2016014187A (he) |
RU (1) | RU2711371C2 (he) |
WO (1) | WO2015166082A1 (he) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014153204A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
EP2940128A1 (en) | 2014-04-30 | 2015-11-04 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Adenovirus comprising an albumin-binding moiety |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
EP3665202A1 (en) | 2017-08-09 | 2020-06-17 | Massachusetts Institute Of Technology | Albumin binding peptide conjugates and methods thereof |
US20200330581A1 (en) * | 2017-10-09 | 2020-10-22 | Keith Black | Oncolytic cancer immunotherapies and methods of use |
WO2020047345A1 (en) | 2018-08-31 | 2020-03-05 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
US20220133823A1 (en) * | 2018-09-10 | 2022-05-05 | Genesail Biotech (Shanghai) Co. Ltd. | A modified oncolytic virus, composition and use thereof |
AU2019383423B2 (en) * | 2018-11-21 | 2023-11-23 | Mayo Foundation For Medical Education And Research | Adenoviruses and methods for using adenoviruses |
SG11202109196XA (en) | 2019-04-29 | 2021-09-29 | Mayo Found Medical Education & Res | Multivalent pd-l1 binding compounds for treating cancer |
JP2022543445A (ja) | 2019-08-05 | 2022-10-12 | メゾブラスト・インターナショナル・エスアーエールエル | ウイルスベクターを含む細胞組成物及び処置方法 |
KR102601875B1 (ko) * | 2020-03-25 | 2023-11-14 | (주)큐리진 | 면역 회피성 항종양 아데노바이러스 |
JP2023537103A (ja) | 2020-08-10 | 2023-08-30 | メゾブラスト・インターナショナル・エスアーエールエル | 細胞組成物及び治療方法 |
CN116271066A (zh) * | 2021-12-13 | 2023-06-23 | 康希诺生物股份公司 | 一种重组腺病毒载体疫苗吸入给药递送系统 |
CN114159556B (zh) * | 2021-12-14 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 一种用于腺病毒载体疫苗免疫增强的蛋白质纳米递送载体 |
KR20230095830A (ko) * | 2021-12-21 | 2023-06-29 | (주)큐리진 | 면역 회피성 항종양 아데노바이러스 |
WO2023120762A1 (ko) * | 2021-12-21 | 2023-06-29 | (주)큐리진 | 면역 회피성 항종양 아데노바이러스 |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
CN115624524B (zh) * | 2022-10-25 | 2023-10-27 | 中国医科大学附属第一医院 | Peg化白蛋白修饰的溶瘤病毒静脉递送制剂的制备及其应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
DE3377363D1 (en) | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
US5328988A (en) | 1987-10-26 | 1994-07-12 | Immunex Corporation | Interleukin-7 |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
KR970005042B1 (ko) | 1993-02-09 | 1997-04-11 | 한일합성섬유공업 주식회사 | 종양괴사인자-알파 뮤테인 |
US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US5641665A (en) | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US7608681B2 (en) * | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
KR101250021B1 (ko) | 2000-05-26 | 2013-04-03 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 완화된 부작용을 갖는 신규 재조합 아데노바이러스 벡터 |
GB0017720D0 (en) | 2000-07-19 | 2000-09-06 | Got A Gene Ab | Modified virus |
WO2007050128A2 (en) * | 2005-05-31 | 2007-05-03 | Vectorlogics, Inc. | Shielded adenoviral vectors and methods of use |
PT2012822E (pt) | 2006-04-28 | 2010-04-27 | Univ Pennsylvania | Proteínas hexon de adenovirus modificadas e suas utilizações |
RU2557319C2 (ru) | 2007-07-16 | 2015-07-20 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ |
CN101781636A (zh) | 2009-01-19 | 2010-07-21 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种含11型腺病毒纤毛蛋白基因的增殖型重组溶瘤腺病毒、其构建方法及其用途 |
ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
EP2558481B1 (en) | 2010-04-14 | 2017-12-20 | Mogam Biotechnology Research Institute | Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same |
EP2940128A1 (en) | 2014-04-30 | 2015-11-04 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Adenovirus comprising an albumin-binding moiety |
-
2014
- 2014-04-30 EP EP14382162.7A patent/EP2940128A1/en not_active Withdrawn
-
2015
- 2015-04-30 BR BR112016025297-7A patent/BR112016025297B1/pt active IP Right Grant
- 2015-04-30 CN CN201580023575.8A patent/CN106471125B/zh active Active
- 2015-04-30 KR KR1020167033433A patent/KR102628234B1/ko active IP Right Grant
- 2015-04-30 CA CA2946650A patent/CA2946650C/en active Active
- 2015-04-30 RU RU2016146664A patent/RU2711371C2/ru active
- 2015-04-30 WO PCT/EP2015/059593 patent/WO2015166082A1/en active Application Filing
- 2015-04-30 US US15/307,408 patent/US10604549B2/en active Active
- 2015-04-30 JP JP2016565257A patent/JP6639412B2/ja active Active
- 2015-04-30 EP EP15720960.2A patent/EP3137599A1/en active Pending
- 2015-04-30 AU AU2015254535A patent/AU2015254535B2/en active Active
- 2015-04-30 MX MX2016014187A patent/MX2016014187A/es unknown
-
2016
- 2016-10-29 IL IL248590A patent/IL248590B/he active IP Right Grant
-
2020
- 2020-02-19 US US16/795,478 patent/US11578104B2/en active Active
-
2023
- 2023-01-10 US US18/152,562 patent/US20230331786A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2015254535A1 (en) | 2016-12-01 |
CA2946650A1 (en) | 2015-11-05 |
RU2016146664A (ru) | 2018-05-30 |
WO2015166082A1 (en) | 2015-11-05 |
US11578104B2 (en) | 2023-02-14 |
BR112016025297A2 (pt) | 2017-10-17 |
EP3137599A1 (en) | 2017-03-08 |
MX2016014187A (es) | 2017-05-03 |
JP2017514483A (ja) | 2017-06-08 |
CA2946650C (en) | 2023-07-11 |
IL248590A0 (he) | 2016-12-29 |
US20170051022A1 (en) | 2017-02-23 |
IL248590B (he) | 2021-01-31 |
RU2016146664A3 (he) | 2018-06-28 |
CN106471125B (zh) | 2021-04-06 |
US10604549B2 (en) | 2020-03-31 |
JP6639412B2 (ja) | 2020-02-05 |
KR20160145825A (ko) | 2016-12-20 |
AU2015254535B2 (en) | 2020-08-13 |
EP2940128A1 (en) | 2015-11-04 |
US20230331786A1 (en) | 2023-10-19 |
KR102628234B1 (ko) | 2024-01-22 |
CN106471125A (zh) | 2017-03-01 |
RU2711371C2 (ru) | 2020-01-16 |
US20200181208A1 (en) | 2020-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11578104B2 (en) | Adenovirus comprising an albumin-binding moiety | |
SM Wold et al. | Adenovirus vectors for gene therapy, vaccination and cancer gene therapy | |
AU2011306845B2 (en) | Oncolytic adenoviral vectors coding for monoclonal anti - CTLA - 4 antibodies | |
JP5075839B2 (ja) | 癌の処置のための腫瘍崩壊性アデノウイルス | |
EP1196616B1 (en) | Replication-competent anti-cancer vectors | |
EP4148126A1 (en) | Immunoevasive anti-tumor adenovirus | |
WO2010086838A2 (en) | Non-ad5 adenoviral vectors and methods and uses related thereto | |
Wolkersdörfer et al. | Trans‐complementing adenoviral vectors for oncolytic therapy of malignant melanoma | |
Zhu et al. | Synergistic therapeutic effect in gastric cancer cells produced by oncolytic adenovirus encoding Drosophila melanogaster deoxyribonucleoside kinase | |
WO2020166727A1 (ja) | ヒト35型アデノウイルスを基板とした腫瘍溶解性ウイルス | |
Henderson et al. | Development of attenuated replication competent adenoviruses (ARCAs) for the treatment of prostate cancer | |
Saini et al. | Importance of viruses and cells in cancer gene therapy | |
Kangasniemi | Improving oncolytic adenoviral therapies for gastrointestinal cancers and tumor initiating cells | |
Särkioja | Adenoviral gene therapy for non-small cell lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2015, OBSERVADAS AS CONDICOES LEGAIS |